DongKook Pharmaceutical Co., Ltd. (086450.KQ)
KRW 15310.0
(-1.73%)
KRW 15310.0
(-1.73%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 88.68 Billion KRW | -3.8% |
| 2022 | 91 Billion KRW | 13.48% |
| 2021 | 80.56 Billion KRW | -17.54% |
| 2020 | 96.47 Billion KRW | 18.68% |
| 2019 | 82.32 Billion KRW | 28.23% |
| 2018 | 64.19 Billion KRW | 11.83% |
| 2017 | 62.53 Billion KRW | 9.0% |
| 2016 | 60.02 Billion KRW | 34.17% |
| 2015 | 42.66 Billion KRW | 26.98% |
| 2014 | 30.91 Billion KRW | 3.87% |
| 2013 | 29.76 Billion KRW | -8.33% |
| 2012 | 32.46 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 26.13 Billion KRW | -23.17% |
| 2024 Q1 | 27.31 Billion KRW | 25.36% |
| 2023 Q2 | 18.07 Billion KRW | -25.77% |
| 2023 FY | - KRW | -3.8% |
| 2023 Q4 | 26.39 Billion KRW | 37.89% |
| 2023 Q3 | 19.13 Billion KRW | 5.89% |
| 2023 Q1 | 24.35 Billion KRW | 10.33% |
| 2022 Q4 | 22.07 Billion KRW | 32.41% |
| 2022 Q3 | 16.66 Billion KRW | -32.6% |
| 2022 Q2 | 24.73 Billion KRW | -11.55% |
| 2022 Q1 | 27.96 Billion KRW | 34.46% |
| 2022 FY | - KRW | 13.48% |
| 2021 Q2 | 19.9 Billion KRW | -15.42% |
| 2021 Q1 | 23.52 Billion KRW | -0.71% |
| 2021 Q4 | 20.79 Billion KRW | 27.23% |
| 2021 Q3 | 16.34 Billion KRW | -17.87% |
| 2021 FY | - KRW | -17.54% |
| 2020 Q2 | 21.97 Billion KRW | -4.81% |
| 2020 Q4 | 23.69 Billion KRW | -18.17% |
| 2020 FY | - KRW | 18.68% |
| 2020 Q1 | 23.08 Billion KRW | -6.49% |
| 2020 Q3 | 28.95 Billion KRW | 31.78% |
| 2019 Q2 | 18.31 Billion KRW | 3.18% |
| 2019 FY | - KRW | 28.23% |
| 2019 Q1 | 17.74 Billion KRW | 15.19% |
| 2019 Q4 | 24.68 Billion KRW | 14.36% |
| 2019 Q3 | 21.58 Billion KRW | 17.88% |
| 2018 Q2 | 15.55 Billion KRW | 4.57% |
| 2018 Q4 | 15.4 Billion KRW | -16.17% |
| 2018 Q3 | 18.38 Billion KRW | 18.19% |
| 2018 FY | - KRW | 11.83% |
| 2018 Q1 | 14.87 Billion KRW | -15.44% |
| 2017 Q1 | 12.81 Billion KRW | -10.45% |
| 2017 Q4 | 17.58 Billion KRW | 21.76% |
| 2017 Q3 | 14.44 Billion KRW | 14.89% |
| 2017 Q2 | 12.57 Billion KRW | -1.94% |
| 2017 FY | - KRW | 9.0% |
| 2016 FY | - KRW | 34.17% |
| 2016 Q2 | 13.93 Billion KRW | 22.55% |
| 2016 Q1 | 11.37 Billion KRW | -9.37% |
| 2016 Q4 | 14.31 Billion KRW | 9.7% |
| 2016 Q3 | 13.04 Billion KRW | -6.39% |
| 2015 Q2 | 7.6 Billion KRW | 4.79% |
| 2015 Q1 | 7.25 Billion KRW | 1.98% |
| 2015 Q3 | 11.84 Billion KRW | 55.77% |
| 2015 Q4 | 12.55 Billion KRW | 5.92% |
| 2015 FY | - KRW | 26.98% |
| 2014 Q3 | 9.01 Billion KRW | 33.12% |
| 2014 Q4 | 7.11 Billion KRW | -21.05% |
| 2014 FY | - KRW | 3.87% |
| 2014 Q1 | 8 Billion KRW | 10.46% |
| 2014 Q2 | 6.77 Billion KRW | -15.45% |
| 2013 Q4 | 7.25 Billion KRW | -16.8% |
| 2013 FY | - KRW | -8.33% |
| 2013 Q1 | 7.3 Billion KRW | -25.56% |
| 2013 Q2 | 6.48 Billion KRW | -11.18% |
| 2013 Q3 | 8.71 Billion KRW | 34.3% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | 9.81 Billion KRW | -2.79% |
| 2012 Q3 | 10.09 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -15161.963% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -1485.23% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | -63.554% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 41.627% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 1636.03% |
| Humedix Co., Ltd. | 54.87 Billion KRW | -61.616% |
| Boditech Med Inc. | 36.48 Billion KRW | -143.051% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 2119.34% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 15099.551% |
| Huons Co., Ltd. | 74.23 Billion KRW | -19.47% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -525.804% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 781.958% |